Jennifer Cardenas
Physician Assistant · Brooklyn, NYNPI 1477067338
Payments from drug & device makers
Across 113 payments — averaging $26.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$353
- Daiichi Sankyo Inc.$269
- AbbVie$189
- Astellas Pharma US Inc$185
- Eisai Inc.$170
- Johnson & Johnson$165
- plus $2K from 31 others
What the payments were for
- Food & beverage$2,63688%
- Education$36712%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 9 | $353 |
| Daiichi Sankyo Inc. | 14 | $269 |
| AbbVie | 4 | $189 |
| Astellas Pharma US Inc | 11 | $185 |
| Eisai Inc. | 7 | $170 |
| Johnson & Johnson | 4 | $165 |
| Merck | 8 | $162 |
| Novartis | 6 | $160 |
| Regeneron Healthcare Solutions, Inc. | 2 | $146 |
| Amgen | 2 | $137 |
| Taiho Oncology, Inc. | 5 | $108 |
| Bristol Myers Squibb | 5 | $105 |
| Pfizer | 2 | $100 |
| E.r. Squibb & Sons, L.L.C. | 4 | $72 |
| Array Biopharma Inc | 3 | $71 |
| Sanofi-aventis U.S. LLC | 1 | $59 |
| Coherus Oncology, Inc. | 2 | $44 |
| Stemline Therapeutics Inc. | 2 | $41 |
| Sobi, Inc | 2 | $41 |
| Puma Biotechnology, Inc. | 2 | $35 |
| Octapharma USA, Inc. | 2 | $35 |
| Beone Medicines USA, Inc. | 1 | $31 |
| Jazz Pharmaceuticals Inc. | 1 | $29 |
| Avyxa Pharma, LLC | 1 | $28 |
| Agios Pharmaceuticals, Inc. | 1 | $28 |
| Boehringer Ingelheim | 1 | $26 |
| Rigel Pharmaceuticals, Inc. | 1 | $24 |
| Seagen Inc. | 1 | $23 |
| Stryker | 1 | $22 |
| Bayer | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Verity Pharmaceuticals Inc. | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Tolmar, Inc. | 1 | $17 |
| Emmaus Medical, Inc. | 1 | $16 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,003 in reported general payments places this provider in the 85th percentile of 11,358 physician assistant providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 93 | $1,499,128 |
| CalquenceAcalabrutinib Maleate | 52 | $792,707 |
| XtandiEnzalutamide | 48 | $666,948 |
| JakafiRuxolitinib Phosphate | 34 | $617,324 |
| RevlimidLenalidomide | 27 | $478,253 |
| TagrissoOsimertinib Mesylate | 23 | $389,840 |
| LynparzaOlaparib | 20 | $358,236 |
| ImbruvicaIbrutinib | 25 | $353,268 |
| KisqaliRibociclib Succinate | 23 | $347,953 |
| Abiraterone Acetate | 67 | $261,932 |
| Everolimus | 11 | $134,433 |
| Somatuline DepotLanreotide Acetate | 13 | $122,166 |
| Sunitinib Malate | 11 | $104,788 |
| XgevaDenosumab | 22 | $70,131 |
| Imatinib Mesylate | 19 | $59,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $100 | $1,540,595147 claims |
| Astellas Pharma US IncXtandi | $185 | $666,94848 claims |
| Incyte CorporationJakafi | $353 | $617,32434 claims |
| Bristol Myers SquibbRevlimid | $105 | $478,25327 claims |
| NovartisKisqali | $160 | $347,95323 claims |
| AmgenXgeva | $137 | $70,13122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Brooklyn
- Kaitlyn NelsonBrooklyn$289K
- Melissa VelezBrooklyn$68K
- Steven KongBrooklyn$66K
- Hong ChenBrooklyn$57K
- Lindsey AxtBrooklyn$52K
- Gregory CelestinBrooklyn$41K
- Henry YuBronx$1M
- Michael AsbachAmherst$962K
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.